The K@W Network:
In the midst of an M&A frenzy in the global pharmaceutical industry, Wharton experts advise companies to keep a watchful eye on runaway valuations and post-merger integration.
The eye-popping price tag for the hepatitis C drug Sovaldi has insurers and patient advocates up in arms. The fault doesn't rest with drugmaker Gilead, Wharton experts say, but with[…]
The data is in, and there is no question that 2013 was the most active year for biotechnology initial public offerings since 2000. Is it a biotech bubble -- or[…]